Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tarnev, Ivaylo
ENSURE-1, NCT05134441 / 2021-000028-36: Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Recruiting	3	1050	Europe, US, RoW	IMU-838 tablets, vidofludimus calcium, Placebo matching IMU-838 tablets, Placebo matching vidofludimus calcium	Immunic AG, Immunic AG	Multiple Sclerosis	09/24	09/32
CALLIPER, NCT05054140 / 2021-000048-23: Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis	Active, not recruiting	2	450	Europe, Canada, US, RoW	IMU-838, Vidofludimus calcium, Placebo matching IMU-838, Placebo Arm	Immunic AG	Multiple Sclerosis	01/25	01/25